Zacks Research Expects Weaker Earnings for Zimmer Biomet

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Zacks Research reduced their Q1 2025 earnings per share (EPS) estimates for Zimmer Biomet in a research note issued on Monday, March 10th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings of $1.77 per share for the quarter, down from their prior estimate of $1.80. The consensus estimate for Zimmer Biomet’s current full-year earnings is $8.22 per share. Zacks Research also issued estimates for Zimmer Biomet’s Q2 2025 earnings at $2.03 EPS, FY2025 earnings at $8.23 EPS, Q2 2026 earnings at $2.23 EPS, Q3 2026 earnings at $2.15 EPS, Q4 2026 earnings at $2.30 EPS, FY2026 earnings at $8.79 EPS and FY2027 earnings at $9.28 EPS.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the previous year, the firm posted $2.20 earnings per share.

A number of other research analysts also recently commented on ZBH. Raymond James dropped their price objective on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and increased their price target for the company from $125.00 to $128.00 in a research note on Tuesday, December 17th. JMP Securities reissued a “market outperform” rating and set a $140.00 price objective on shares of Zimmer Biomet in a report on Friday, February 7th. Barclays lowered their target price on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a report on Monday, February 10th. Finally, Royal Bank of Canada cut their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Stock Performance

NYSE:ZBH opened at $104.10 on Tuesday. The firm has a market capitalization of $20.72 billion, a PE ratio of 23.39, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The business’s fifty day moving average price is $105.65 and its 200 day moving average price is $107.05. Zimmer Biomet has a 12 month low of $97.69 and a 12 month high of $133.90.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date is Monday, March 31st. Zimmer Biomet’s dividend payout ratio is presently 21.57%.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the firm’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares of the company’s stock, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.95% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Zimmer Biomet

A number of large investors have recently made changes to their positions in the stock. Dodge & Cox grew its position in Zimmer Biomet by 12.0% during the fourth quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider’s stock worth $2,019,480,000 after buying an additional 2,044,645 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of Zimmer Biomet by 1.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,760,444 shares of the medical equipment provider’s stock worth $1,559,147,000 after acquiring an additional 176,337 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Zimmer Biomet by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock worth $524,942,000 after acquiring an additional 125,852 shares during the period. Van ECK Associates Corp increased its stake in Zimmer Biomet by 5.9% in the 4th quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider’s stock valued at $417,814,000 after purchasing an additional 218,688 shares in the last quarter. Finally, Franklin Resources Inc. increased its stake in Zimmer Biomet by 398.7% in the 4th quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider’s stock valued at $369,469,000 after purchasing an additional 2,796,372 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.